Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients

Alemtuzumab demonstrated a broad treatment effect in improving preexisting disability. These findings may influence treatment decisions in patients with early, active relapsing-remitting MS displaying neurological deficits. ClinicalTrials.gov Identifier NCT00050778.